CVS HEALTH Corp (CVS) shareholders
CVSNYSERetail-Drug Stores and Proprietary StoresFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 19/3029% below fair value
$89.79+0.27 (+0.30%)
Close on Nov 12, 2026Market cap $114.84BP/E 10.5Yield 2.96%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
89.2%
1.14B of 1.28B shares
Institutional holders
2,064
323 new, 108 sold out
Net institutional buying
39M
In Q2 2026
Insider trades, 12 months
1 buys · 8 sales
Net sold $321.71M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 105,292,588 | 8.30% | 13G (passive) amendment | Jun 30, 2025 |
| Vanguard Capital Management | 95,598,528 | 7.51% | 13G (passive) | Mar 31, 2026 |
| Capital World Investors | 68,785,990 | 5.50% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CVS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 123,223,409 | 9.63% | $12.75B | −2,696,444 | 0.19% |
| Vanguard Capital Management LLC | 83,315,369 | 6.51% | $8.62B | +665,293 | 0.18% |
| Capital World Investors | 74,951,955 | 5.86% | $7.75B | −2,296,687 | 0.92% |
| State Street Corp | 60,283,408 | 4.71% | $6.24B | +961,227 | 0.18% |
| Dodge & Cox | 50,012,765 | 3.91% | $5.17B | −1,767,351 | 2.71% |
| Wellington Management Group Llp | 33,801,113 | 2.64% | $3.50B | +11,233,381 | 0.60% |
| Geode Capital Management, LLC | 29,899,653 | 2.34% | $3.08B | +440,611 | 0.16% |
| FMR LLC | 28,920,617 | 2.26% | $2.99B | −2,276,273 | 0.13% |
| Vanguard Portfolio Management LLC | 26,637,259 | 2.08% | $2.76B | +639,911 | 0.12% |
| Capital Research Global Investors | 24,329,151 | 1.90% | $2.52B | +4,316,819 | 0.35% |
| Price T Rowe Associates Inc /Md/ | 24,203,884 | 1.89% | $2.50B | +420,739 | 0.25% |
| Bank Of America Corp /De/ | 23,188,670 | 1.81% | $2.40B | +13,836,701 | 0.15% |
| JPMorgan Chase & Co | 22,112,970 | 1.73% | $2.29B | −7,414,155 | 0.13% |
| Invesco Ltd. | 20,595,431 | 1.61% | $2.13B | −4,543,515 | 0.17% |
| Morgan Stanley | 18,606,028 | 1.45% | $1.92B | +780,906 | 0.10% |
| Norges Bank | 18,038,922 | 1.41% | $1.87B | New | 0.19% |
| Capital International Investors | 15,387,600 | 1.20% | $1.59B | −4,622 | 0.33% |
| Goldman Sachs Group Inc | 13,411,807 | 1.05% | $1.39B | +772,006 | 0.12% |
| Charles Schwab Investment Management Inc | 13,259,314 | 1.04% | $1.37B | −415,611 | 0.18% |
| Davis Selected Advisers | 11,865,916 | 0.93% | $1.23B | −373,750 | 5.27% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2,064 | 1.14B | 89.2% | 323 / 778 | 732 / 108 | 114M | 74M |
| Q1 2026 | 1,877 | 1.11B | 86.4% | 159 / 726 | 747 / 197 | 201M | 105M |
| Q4 2025 | 1,948 | 1.14B | 88.7% | 272 / 704 | 723 / 119 | 100M | 92M |
| Q3 2025 | 1,838 | 1.13B | 88.3% | 213 / 670 | 726 / 109 | 98M | 72M |
| Q2 2025 | 1,760 | 1.11B | 86.4% | 184 / 636 | 730 / 157 | 92M | 70M |
| Q1 2025 | 1,754 | 1.08B | 84.8% | 278 / 536 | 756 / 170 | 116M | 77M |
| Q4 2024 | 1,670 | 1.05B | 82.1% | 231 / 370 | 932 / 368 | 125M | 103M |
| Q3 2024 | 1,844 | 1.03B | 80.8% | 158 / 490 | 1012 / 207 | 181M | 86M |
| Q2 2024 | 1,914 | 1.04B | 81.3% | 131 / 574 | 1044 / 371 | 137M | 173M |
| Q1 2024 | 2,182 | 1.08B | 84.3% | 132 / 780 | 1048 / 180 | 79M | 64M |
| Q4 2023 | 2,263 | 1.07B | 83.3% | 308 / 668 | 1094 / 126 | 112M | 47M |
| Q3 2023 | 2,118 | 1.00B | 78.3% | 110 / 783 | 1024 / 173 | 86M | 82M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1,036 funds held CVS in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CVS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 40,502,867 | 3.17% | $4.19B | 0.18% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 33,064,695 | 2.59% | $3.42B | 0.20% | Jun 30, 2026 |
| Dodge & Cox Stock Fund | 31,708,094 | 2.48% | $3.28B | 2.77% | Jun 30, 2026 |
| Washington Mutual Investors Fund | 31,634,083 | 2.47% | $3.30B | 1.52% | Jul 31, 2026 |
| Income Fund of America | 23,692,996 | 1.85% | $2.47B | 1.67% | Jul 31, 2026 |
| American Balanced Fund | 17,930,421 | 1.40% | $1.85B | 0.64% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 17,551,259 | 1.37% | $1.82B | 0.20% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 16,280,513 | 1.27% | $1.48B | 0.18% | May 31, 2026 |
| Vanguard Value Index Fund | 12,146,799 | 0.95% | $1.26B | 0.49% | Jun 30, 2026 |
| American Mutual Fund | 10,479,452 | 0.82% | $1.09B | 0.93% | Jul 31, 2026 |
| Vanguard Health Care Fund | 9,210,092 | 0.72% | $961.81M | 2.52% | Jul 31, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 9,013,998 | 0.70% | $932.50M | 2.30% | Jun 30, 2026 |
| American Funds Fundamental Investors | 8,500,940 | 0.66% | $879.42M | 0.49% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 6,926,554 | 0.54% | $716.55M | 0.20% | Jun 30, 2026 |
| Vanguard Equity Income Fund | 6,245,709 | 0.49% | $646.12M | 0.99% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| J. David Joyner | President, CEO and Chair, Director | 70,349 | 0.01% | Apr 2, 2026 |
| Prem S. Shah | EVP and Group President | 88,516 | 0.01% | Nov 6, 2026 |
| James David Clark | SVP, Cont & Chief Acct Officer | 27,606 | 0.00% | Jun 29, 2026 |
| Brian Newman | EVP, Chief Financial Officer | 3,038 | 0.00% | Jun 1, 2026 |
| Amy Compton-Phillips | EVP, Chief Medical Officer | 9,592 | 0.00% | Jun 1, 2026 |
| Tilak Mandadi | EVP, Chief Exp & Tech Officer | 10,133 | 0.00% | May 11, 2026 |
| Steven H. Nelson | EVP and President, Aetna | 2,924 | 0.00% | Apr 2, 2026 |
| Samrat S. Khichi | EVP, CPO and General Counsel | 33,421 | 0.00% | Apr 2, 2026 |
| Heidi B. Capozzi | EVP and Chief People Officer | 13,108 | 0.00% | Apr 2, 2026 |
| Thomas F. Cowhey | EVP and CFO | 41,109 | 0.00% | Apr 3, 2025 |
| Fernando Aguirre | Director | 11,181 | 0.00% | May 22, 2026 |
| Larry Robbins | Director | 4,824,799 | 0.38% | May 21, 2026 |
| C. David Brown Ii | Director | 129,316 | 0.01% | May 15, 2026 |
| J. Scott Kirby | Director | 14,434 | 0.00% | May 15, 2026 |
| Guy P. Sansone | Director | 15,106 | 0.00% | May 15, 2026 |
| John E. Gallina | Director | 582 | 0.00% | May 15, 2026 |
| Michael F. Mahoney | Director | 6,555 | 0.00% | May 15, 2026 |
| Leslie V. Norwalk | Director | 7,376 | 0.00% | May 15, 2026 |
| Anne A. Finucane | Director | 22,747 | 0.00% | May 15, 2026 |
| Alecia A. Decoudreaux | Director | 2,970 | 0.00% | May 15, 2026 |
| Douglas H. Shulman | Director | 5,929 | 0.00% | May 15, 2026 |
| Jeffrey R. Balser | Director | 15,717 | 0.00% | May 15, 2026 |
| Roger N. Farah | Director | 19,438 | 0.00% | Dec 2, 2025 |
| Nancy Ann Deparle | Director | 34,169 | 0.00% | Nov 25, 2024 |
| Mary L. Schapiro | Director | 11,844 | 0.00% | Nov 25, 2024 |
| Jean Pierre Millon | Director | 112,217 | 0.01% | Nov 25, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Prem S. Shah EVP and Group President | Nov 6, 2026 | Buy | +23,855 | $83.89 | $2.00M | 88,516 |
| James David Clark SVP, Cont & Chief Acct Officer | Jun 26, 2026 | Tax withholding | −454 | $90.98 | $41.30K | 27,606 |
| Brian Newman EVP, Chief Financial Officer | May 31, 2026 | Tax withholding | −2,478 | $90.98 | $225.45K | 3,008 |
| Amy Compton-Phillips EVP, Chief Medical Officer | May 31, 2026 | Tax withholding | −7,618 | $90.98 | $693.09K | 9,557 |
| Fernando Aguirre Director | May 21, 2026 | Returned to company | −1,563 | $93.50 | $146.14K | 10,513 |
| Larry Robbins Director | May 21, 2026 | Sale | −370,462 | $93.45 | $34.62M | 4,824,799 |
| Fernando Aguirre Director | May 20, 2026 | Returned to company | −30,437 | $93.78 | $2.85M | 12,076 |
| Larry Robbins Director | May 20, 2026 | Sale | −152,691 | $94.81 | $14.48M | 5,262,942 |
| Larry Robbins Director | May 20, 2026 | Sale | −797,628 | $93.48 | $74.56M | 5,415,633 |
| Larry Robbins Director | May 20, 2026 | Sale | −800 | $96.28 | $77.02K | 5,195,261 |
| Larry Robbins Director | May 20, 2026 | Sale | −66,881 | $95.67 | $6.40M | 5,196,061 |
| Larry Robbins Director | May 19, 2026 | Sale | −151 | $95.18 | $14.37K | 6,213,261 |
| Larry Robbins Director | May 19, 2026 | Sale | −1,983,387 | $94.45 | $187.33M | 6,213,412 |
| Guy P. Sansone Director | May 14, 2026 | Award | +1,447 | $97.15 | $140.58K | 15,106 |
| Leslie V. Norwalk Director | May 14, 2026 | Award | +1,447 | $97.15 | $140.58K | 7,376 |
| J. Scott Kirby Director | May 14, 2026 | Award | +1,447 | $97.15 | $140.58K | 14,434 |
| Fernando Aguirre Director | May 14, 2026 | Award | +1,563 | $97.15 | $151.85K | 42,513 |
| C. David Brown Ii Director | May 14, 2026 | Award | +1,544 | $97.15 | $150.00K | 129,316 |
| Jeffrey R. Balser Director | May 14, 2026 | Award | +2,058 | $97.15 | $199.93K | 15,717 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | May 8, 2026 | Sale | −69,551 | $89.58 | $6.23M | 10,133 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | Apr 1, 2026 | Tax withholding | −3,634 | $72.49 | $263.43K | 79,684 |
| Heidi B. Capozzi EVP and Chief People Officer | Apr 1, 2026 | Tax withholding | −1,334 | $72.49 | $96.70K | 13,023 |
| Samrat S. Khichi EVP, CPO and General Counsel | Apr 1, 2026 | Tax withholding | −3,541 | $72.49 | $256.69K | 33,421 |
| Steven H. Nelson EVP and President, Aetna | Apr 1, 2026 | Tax withholding | −2,432 | $72.49 | $176.30K | 2,900 |
| James David Clark SVP, Cont & Chief Acct Officer | Apr 1, 2026 | Tax withholding | −3,262 | $72.49 | $236.46K | 15,457 |
| J. David Joyner President, CEO and Chair, Director | Apr 1, 2026 | Tax withholding | −8,029 | $72.49 | $582.02K | 70,349 |
| Prem S. Shah EVP and Group President | Apr 1, 2026 | Tax withholding | −1,484 | $72.49 | $107.58K | 64,356 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | Mar 31, 2026 | Award | +22,277 | $71.82 | $1.60M | 88,543 |
| Brian Newman EVP, Chief Financial Officer | Mar 31, 2026 | Award | +19,493 | $71.82 | $1.40M | 41,354 |
| Heidi B. Capozzi EVP and Chief People Officer | Mar 31, 2026 | Award | +10,025 | $71.82 | $720.00K | 84,450 |
| Samrat S. Khichi EVP, CPO and General Counsel | Mar 31, 2026 | Award | +12,531 | $71.82 | $899.98K | 38,139 |
| Steven H. Nelson EVP and President, Aetna | Mar 31, 2026 | Award | +22,277 | $71.82 | $1.60M | 43,606 |
| James David Clark SVP, Cont & Chief Acct Officer | Mar 31, 2026 | Award | +11,138 | $71.82 | $799.93K | 35,539 |
| J. David Joyner President, CEO and Chair, Director | Mar 31, 2026 | Award | +86,326 | $71.82 | $6.20M | 160,860 |
| Amy Compton-Phillips EVP, Chief Medical Officer | Mar 31, 2026 | Award | +5,569 | $71.82 | $399.97K | 58,660 |
| Prem S. Shah EVP and Group President | Mar 31, 2026 | Award | +25,062 | $71.82 | $1.80M | 62,852 |
| John E. Gallina Director | Mar 19, 2026 | Award | +582 | $71.86 | $41.82K | 582 |
| J. David Joyner President and CEO, Director | Feb 28, 2026 | Tax withholding | −1,944 | $79.90 | $155.33K | 49,996 |
| Samrat S. Khichi EVP, CPO and General Counsel | Feb 28, 2026 | Tax withholding | −7,886 | $79.60 | $627.73K | 29,775 |
| Prem S. Shah EVP and Group President | Jan 1, 2026 | Tax withholding | −247 | $80.13 | $19.79K | 61,509 |
| James David Clark SVP, Cont & Chief Acct Officer | Dec 1, 2025 | Tax withholding | −220 | $79.10 | $17.40K | 24,401 |
| Roger N. Farah Director | Nov 30, 2025 | Tax withholding | −9,748 | $80.36 | $783.35K | 19,438 |
| Heidi B. Capozzi EVP and Chief People Officer | Nov 30, 2025 | Tax withholding | −9,470 | $80.36 | $761.01K | 11,415 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | Nov 30, 2025 | Tax withholding | −6,575 | $80.36 | $528.37K | 74,085 |
| Jeffrey R. Balser Director | Nov 20, 2025 | Award | +1,775 | $76.04 | $134.97K | 13,659 |
| Leslie V. Norwalk Director | Nov 20, 2025 | Award | +1,652 | $76.04 | $125.62K | 5,929 |
| C. David Brown Ii Director | Nov 20, 2025 | Award | +1,775 | $76.04 | $134.97K | 127,772 |
| J. Scott Kirby Director | Nov 20, 2025 | Award | +1,652 | $76.04 | $125.62K | 12,987 |
| Douglas H. Shulman Director | Nov 20, 2025 | Award | +1,652 | $76.04 | $125.62K | 5,929 |
| Fernando Aguirre Director | Nov 20, 2025 | Award | +1,800 | $76.04 | $136.87K | 40,950 |
| Anne A. Finucane Director | Nov 20, 2025 | Award | +591 | $76.04 | $44.94K | 591 |
| Guy P. Sansone Director | Nov 20, 2025 | Award | +1,652 | $76.04 | $125.62K | 13,659 |
| Prem S. Shah EVP and Group President | Aug 31, 2025 | Tax withholding | −6,995 | $73.15 | $511.68K | 60,632 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | Aug 31, 2025 | Tax withholding | −12,834 | $73.15 | $938.81K | 63,952 |
| Anne A. Finucane Director | Aug 20, 2025 | Sale | −7,500 | $71.02 | $532.65K | 22,156 |
| Guy P. Sansone Director | Jun 5, 2025 | Buy | +1,570 | $63.70 | $100.01K | 12,007 |
| Brian Newman EVP, Chief Financial Officer | May 31, 2025 | Award | +21,861 | $64.04 | $1.40M | 21,861 |
| Amy Compton-Phillips EVP, Chief Medical Officer | May 31, 2025 | Award | +6,246 | $64.04 | $399.99K | 53,091 |
| Amy Compton-Phillips EVP, Chief Medical Officer | May 31, 2025 | Award | +46,845 | $64.04 | $3.00M | 46,845 |
| Guy P. Sansone Director | May 15, 2025 | Award | +2,077 | $60.47 | $125.60K | 10,437 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
1.40%
18M shares short
Days to cover
2.8
At 6M shares a day
Change since last report
+10.4%
From 16M shares
Short volume, 20 days
27.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cvs Health's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,918 shares on Aug 27, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Fernando Aguirre Director | May 22, 2026 | 32,000 | $3.03M | May 20, 2026 | Compensation |
| Roger N. Farah Director | May 21, 2026 | 2,817 | $263.89K | May 21, 2026 | Compensation |
| Tilak Mandadi Officer | May 8, 2026 | 69,551 | $6.23M | May 8, 2026 | Restricted Stock |
| Anne A. Finucane Director | Aug 19, 2025 | 7,500 | $532.28K | Aug 20, 2025 | Director Compensation |
| James David Clark Officer | Mar 5, 2025 | 7,513 | $498.49K | Mar 5, 2025 | STOCK OPTION EXERCISE |
| Prem S. Shah Officer | Feb 16, 2024 | 29,473 | $2.27M | Feb 16, 2024 | DRIP |
| James David Clark Officer | Aug 3, 2023 | 25,759 | $1.93M | Aug 3, 2023 | RESTRICTED STOCK |
See a number that looks wrong?